Anja Welt

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL.

Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL.

Journal: ESMO real world data and digital oncology

Published: April 20, 2026

SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [68Ga]Ga-DOTATOC and [68Ga]Ga-SSO120 with [18F]FDG PET.

SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [68Ga]Ga-DOTATOC and [68Ga]Ga-SSO120 with [18F]FDG PET.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 14, 2026

Diagnostic value of [68Ga]Ga-FAPI-46 PET in comparison to [18F]FDG PET in triple-negative breast cancer and potential for theranostic application.

Diagnostic value of [68Ga]Ga-FAPI-46 PET in comparison to [18F]FDG PET in triple-negative breast cancer and potential for theranostic application.

Journal: Scientific reports

Published: January 05, 2026

Comparison between [68Ga]Ga-FAPI-46 and [18F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer.

Comparison between [68Ga]Ga-FAPI-46 and [18F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer.

Journal: EJNMMI research

Published: September 09, 2025

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Journal: International journal of cancer

Published: August 06, 2025

Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy.

Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy.

Journal: Scientific reports

Published: November 06, 2024

Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.

Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.

Journal: Oncology research and treatment

Published: September 19, 2024

Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Journal: International journal of cancer

Published: July 31, 2024

Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer.

Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer.

Journal: Geburtshilfe und Frauenheilkunde

Published: April 19, 2024

Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence.

Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence.

Journal: Nature cancer

Published: March 05, 2024

Chest wall resections for advanced breast cancer: a narrative review.

Chest wall resections for advanced breast cancer: a narrative review.

Journal: Journal of thoracic disease

Published: September 13, 2023

Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological Inpatients.

Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological Inpatients.

Journal: Cancers

Published: April 06, 2023

Showing 1-12 of 33

Last Updated: 09/26/2026